Poseida Therapeutics Inc (NAS:PSTX)

$ 3.43 0.51 (17.47%) Market Cap: 332.46 Mil Enterprise Value: 154.31 Mil PE Ratio: 0 PB Ratio: 3.18 GF Score: 35/100

Poseida Therapeutics Inc P-BCMA-ALLO1 Clinical Data Call Transcript
Dec 10, 2023
Poseida Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023
Poseida Therapeutics Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) Transcript
May 30, 2023
Poseida Therapeutics Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Poseida Therapeutics Inc at HC Wainwright Cell Therapy Virtual Conference Transcript
Feb 28, 2023
Poseida Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
Nov 30, 2022
Poseida Therapeutics Inc at Stifel Healthcare Conference Transcript
Nov 16, 2022
Poseida Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
Poseida Therapeutics Inc Collaboration and Poseida's Novel Approach to Allogeneic Cell Therapy - Corporate Call Transcript
Aug 03, 2022
Poseida Therapeutics Inc at Bank of America Healthcare Conference Transcript
May 10, 2022

Poseida Therapeutics Inc at Bank of America Global Healthcare Conference Transcript

May 10, 2023 / 10:15PM GMT

Release Date Price: $3.39 (-0.29%)

Transcript 10-Q8-K

Alec Stranahan

Bank of America - Analyst

Let's get going. Hey, everyone. Welcome to day two of the 2023 BofA Healthcare Conference. Thanks for joining the session with Poseida Therapeutics. My name is Alec Stranahan. I'm Vice President and Senior Biotech Analyst covering Poseida here at BofA. And I'm pleased to be joined today by Mark Gergen, Chairman and Chief Executive Officer of Poseida. Mark, thanks for joining.

Mark Gergen

Poseida Therapeutics, Inc. - CEO & Chairman

Thanks for having us. Happy to be here.

Questions & Answers

Alec Stranahan

Bank of America - Analyst

Perfect. So given we've got 15 minutes, we'll just jump straight into the Q&A. But if anyone in the audience has a question, feel free to raise your hand and we'll bring you a mic and you can ask it throughout.

So Mark, maybe just to start, you guys have some pretty high-profile collaborations, Roche, Takeda. How should we be thinking about timelines, study starts, time to data for these partnered assets and maybe the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.